AXNX — Axonics Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $3.63bn
- $3.28bn
- $366.38m
Annual cashflow statement for Axonics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -79.9 | -54.9 | -80.1 | -59.7 | -6.09 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 9.67 | 16.5 | 33.4 | 54.1 | 64.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -14.4 | -47 | -9.81 | -2.93 | -66.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -83.5 | -83.7 | -47.3 | 3.19 | -2.02 |
| Capital Expenditures | -1.34 | -2.94 | -2.26 | -2.22 | -3.55 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 46.6 | 12.6 | -141 | -118 | -113 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 45.3 | 9.65 | -143 | -120 | -117 |
| Financing Cash Flow Items | -7.14 | -9.01 | -11.4 | -0.192 | -7.63 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 111 | 144 | 171 | 134 | -3.38 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 72.8 | 70.1 | -20.3 | 18 | -121 |